Learn More
PURPOSE The purpose of this study was to determine whether addition of the synthetic rexinoid bexarotene (Targretin; Eisai Inc, Woodcliff Lake, NJ) to standard first-line carboplatin and paclitaxel(More)
PURPOSE This study evaluated whether the combination of the synthetic rexinoid bexarotene with first-line cisplatin/vinorelbine therapy provides additional survival benefit in patients with advanced(More)
7358 Background: NSCLC is one of the leading causes of cancer-related deaths world wide. Targretin® (bexarotene) is a selective RXR agonist approved for the treatment of CTCL. Bexarotene has also(More)